The dosage of Praluent for pediatric patients aged 8 years and older with HeFH is based on body weight and can be adjusted based on LDL-C lowering response. The Food and Drug Administration (FDA) has ...
The Food and Drug Administration on Tuesday approved a once-monthly dose form of the cholesterol drug Praluent. The drug, co-developed by Regeneron Pharmaceuticals and Sanofi, first earned FDA ...
(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) announced the FDA has extended the approval of Praluent as an adjunct to diet and other low-density lipoprotein cholesterol lowering therapies to ...
Regeneron's Praluent injection gets FDA approval to treat kids with genetic form of high cholesterol
Regeneron Pharmaceuticals (NASDAQ:REGN) has received approval from the U.S. Food & Drug Administration (FDA) for its Praluent (alirocumab) injection to treat children with genetic form of high ...
Regeneron Pharmaceuticals, Inc. REGN announced that the FDA extended the approval of the cholesterol drug Praluent’s (alirocumab) label. The regulatory body approved the drug as an adjunct to diet and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results